THE EFFECT OF COMBINATION USED OF METFORMIN AND TELMISARTAN TOWARDS THE WAIST CIRCUMFERENCE IN PATIENTS WITH METABOLIC SYNDROME
STEPHANIE FOO SHI YI, Dr. Cornelia Wahyu Danawati, Ph.D. Sp.PD
2014 | Skripsi | PENDIDIKAN DOKTER-
Background: Metabolic syndrome is a cluster of conditions include central obesity, hyperglycemia, dyslipidemia, and elevated blood pressure. It represents a significant risk factor for the development of cardiovascular disease (CVD) and type 2 diabetes mellitus. Metformin is reported to promote weight loss and reduce appetite and telmisartan reduces visceral fat accumulation, increase energy expenditure and improve lipid metabolism. Objective: To understand the influence of combination used of metformin and telmisartan towards the waist circumference of patients with metabolic syndrome. Method: Using quasi experiment – one group pre-test post-test design, 27 subjects that fulfil the metabolic syndrome diagnosis based on IDF 2005 criteria, have hypertension, currently receiving insulin therapy at Internal Medicine’s endocrinology Polyclinic in RSUP DR. Sardjito, Yogyakarta received combination metformin (500mg increased slowly to 2g) and once daily dose of telmisartan (80mg). Waist circumference before and after therapy with combination of metformin and telmisartan is measured. Result: No statistically significant (P= 0.278) difference in waist circumference between before (mean ± SD= 97.2 ± 6.537) and after therapy (mean ± SD= 96.19 ± 6.581) with combination of metformin and telmisartan in patient with metabolic syndrome. Conclusion: There is no statistically significant difference in waist circumference between before and after therapy with combination of metformin and telmisartan in patient with metabolic syndrome.
Kata Kunci : metabolic syndrome, central obesity, insulin resistance, metformin, telmisartan, waist circumference
